» BIOPROCESSING


»


14. M2p-labs Micro Bioreactor Web Site. Available at: http://www.m2p-labs.com/products/ instruments. Accessed February 6, 2015.


15. 16. 17. 18. 19. 20.


Cheung L, et al. Developing an automated high-throughput system for cell culture process development. Presented at International Business Communications Life Sciences’ BioProcess International Conference. 2008, Sep 22-26; Anaheim, CA.


Legmann R, et al. A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol Bioeng. 2009;104(6):1107-20.


Lacki KM, et al. High-throughput process development: determination of dynamic binding capacity using a microtiter plates filled with chromatography resins. Presented at the American Chemical Society’s 234th National Meeting. 2007 Aug 19-23; Boston, MA.


Coffman JL, et al. High-throughput screening of chromatographic separations: I. Method development and column modeling. Biotechnol Bioeng. 2008 Jul 1;100(4):605-618.


Tecan. Mannedorf (CH): Tecan Trading, AG; Freedom Evo® Overview; 2014. Available at: http://www.tecan.com/platform/apps/product/index.asp?MenuID=2694&ID=5270&Me nu=1&Item=21.1.8. Accessed February 6, 2015.


Chhatre S, Titchener-Hooker NJ. Predicting process scale chromatographic performance using micro scale-down devices. Presented at University College of London’s Innovative Manufacturing Research Center, steering group meeting. 2008 Sep 17; London, United Kingdom.


21. 22. 23. 24. 25. 26.


Kelley BD, et al. High-throughput screening of chromatographic separations: IV. Ion- exchange. Biotechnol Bioeng. 2008;100(5):950-963.


Kelley BD, et al. Weak partitioning chromatography for anion exchange purification of monoclonal antibodies. Biotechnol Bioeng. 2008;101(3):553-566.


Lacki KM, et al. Accelerated development of a downstream purification process for production of monoclonal antibodies: a case study. Presented at the 13th Recovery of Biological Products Conference. 2008 Jun 22-27; Quebec City, Canada.


Kramarczyk JF, et al. High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol Bioeng. 2008;100(4):707-720.


Rege K, et al. High-throughput process development for recombinant protein purification. Biotechnol Bioeng. 2006;93(4):618-30.


Linden T. Untersuchungen zum inneren transport bei der proteinadsorption an porose medien mittels konfokaler laser-rester-mikroskopie [Investigations of internal transport during protein adsorption on porous media using confocal laser scanning microscopy] [dissertation]. Dusseldorf (DE): Heinrich-Heine University Dusseldorf; 2001 Dec. Section 3.7.3, Einkomponentenadsorption monoklonaler antikorper oder BSA [Single component adsorption of monoclonal antibodies or BSA]; p. 87-88. German.


27.


Bergander T, et al. High-throughput process development: determination of dynamic binding capacity using microtiter filter plates filled with chromatography resin. Biotechnol Prog. 2008;24(3):632-639.


28. Wenger MD, et al. An automated microscale chromatographic purification of virus-like particles as a strategy for process development. Biotechnol Appl Biochem. 2007;47(Pt 2):131-139.


29. 30. 31.


Bhambure R, et al. High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol. 2011;29(3):127-135.


Rodrigo G, Nilsson-Valimaa K. Developing a MAb aggregate removal step by high- throughput process development. BioPharm International. 2010;23(4):45-61.


High-Throughput Process Development Conference. Extended reports from the second international conference on high-throughput process development; Avignon, France, 4-7 June 2012. Buckinghamshire (UK): GE Healthcare UK Ltd; 2012 Nov. 52 p. Available from: https:// www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1354036544405/ litdoc29034193_20140930090841.pdf.


32. 33.


Chollangi S, et al. Accelerating purification process development of an early phase MAb with high-throughput automation. Part 1. Bioprocess Int. 2014;12(3): 48-52.


Chollangi S, et al. Accelerating purification process development of an early phase MAb with high-throughput automation. Part 2. Bioprocess Int. 2014 Mar;12(4): 32-41.


34. Wierling PS, et al. High-throughput screening of packed-bed chromatography coupled with SELDI-TOF MS analysis: monoclonal antibodies versus host cell protein. Biotechnol Bioeng. 2007;98(2):440-450.


48 | | January/February 2015 35.


Lacki KM, et al. Development and scale-up of a downstream process for a monoclonal antibody: a case study. Presented at the Society for Biological Engineering’s Second International Conference on Accelerating Biopharmaceutical Development; 2009 Mar 9-12; Coronado, CA.


36. Oelmeier SA, et al. Application of an aqueous two-phase systems high-throughput screening method to evaluate mAb HCP separation. Biotechnol Bioeng. 2011;108(1):69-81.


Author Biographies


Susan Dana Jones, PhD, Vice President and Principal Consultant with BioProcess Technology Consultants, is a seasoned biotechnology entrepreneur with experience in product development, outsourcing, and strategic planning. Dr. Jones is a subject matter expert in cell line development and characterization for biosimilar, new biopharmaceutical, and vaccine development programs. She has a broad knowledge of regulatory requirements for manufacturing products for human use and has prepared CMC sections of multiple regulatory submissions. She currently serves on the Board of Directors of Gene Solutions, the Scientific Advisory Board of Symphogen, and is a member of the Editorial Advisory Board of BioProcess International. She received her PhD in Genetics from the University of California, San Francisco.


Thomas C. Ransohoff, MS, Vice President and Principal Consultant at BioProcess Technology Consultants, is an expert in development and scale-up of biopharmaceutical processes, separations and purification technologies, cGMP manufacturing, and management of technology- based start-up businesses. He holds a BS in Chemical Engineering from MIT and an MS in Chemical Engineering from the University of California, Berkeley.


Frank Castillo, PhD, Senior Consultant with BioProcess Technology Consultants, has over 30 years of experience in the development and manufacturing of biopharmaceuticals with expertise in project management and process development for monoclonal antibodies, recombinant proteins, gene therapy vectors, and cell-based therapies. He holds a PhD in Microbiology from the College of Medicine and Dentistry of New Jersey.


Frank J. Riske, PhD, Senior Consultant at BioProcess Technology Consultants, has over 25 years of experience in the biopharmaceutical industry. Dr. Riske has extensive experience in the development of downstream processes for cytokines, proteins, and virus from plasma, E coli, Pichia, and mammalian systems and in the development and manufacture of novel drug delivery systems. Dr. Riske received his BS in Biology from Fairfield University and a PhD in Biochemistry and Microbiology from Rutgers University, and completed a post-doctoral position at Hoffmann-LaRoche.


Howard L. Levine, PhD, President and Principal Consultant of BioProcess Technology Consultants and Managing Director of BPTC Europe, has over 30 years of experience in the development and commercialization of biopharmaceutical products. He has worked on products including vaccines, cell therapy, fusion proteins, antibodies, natural products, cytokines, and other recombinant proteins. Dr. Levine earned a PhD in Chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76